What is claimed is:

1. A pharmaceutical formulation, comprising:

1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable topical carrier.

2. The pharmaceutical formulation of claim **1**, wherein the pharmaceutically acceptable topical carrier comprises one or more members selected from polymers, thickeners, buffers, neutralizers, chelating agents, preservatives, surfactants or emulsifiers, antioxidants, waxes or oils, emollients, sunscreens, and a solvent or mixed solvent system.

3. The pharmaceutical formulation of claim **1**, wherein the pharmaceutically acceptable topical carrier comprises a solvent system and a chelating agent; wherein the solvent system comprises ethanol and propylene glycol; and wherein

the chelating agent is ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical formulation, comprising:

1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof;

a solvent system and

a chelating agent.

5. The pharmaceutical formulation of claim **4**, wherein the solvent system comprises ethanol.

6. The pharmaceutical formulation of claim **4**, wherein the solvent system consists of ethanol.

7. The pharmaceutical formulation of claim **4**, wherein the solvent system comprises ethanol and propylene glycol.

8. The pharmaceutical formulation of claim **4**, wherein the chelating agent is ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical formulation of claim **8**, wherein the ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof, is present in a concentration of from about 0.005% to about 2.0% w/w.

10. The pharmaceutical formulation of claim **4**, wherein the 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof, is present in a concentration of about 5% w/w.

11. The pharmaceutical formulation of claim **4**, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* by topical application of the formulation to the toenail.

12. A pharmaceutical formulation, comprising:

about 5% w/w 1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof;

propylene glycol;

ethanol; and

ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical formulation of claim **12**, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* by topical application of the formulation to the toenail.

14. The pharmaceutical formulation of claim **12**, wherein the ethylene diamine tetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof, is present in a concentration of from about 0.005% to about 2.0% w/w.

15. The pharmaceutical formulation of claim **14**, wherein the formulation is suitable for the treatment of onychomycosis of a toenail due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* by topical application of the formulation to the toenail.

* * * * *